Ashley Delcambre, OD
Optometrist · New Orleans, LANPI 1558914077
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,370 of the $6,469 with a category attached, or 83.0%. 21 manufacturers reported payments, led by Alcon at 35.9% of the total. Among optometrist clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $54.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$593
- Johnson & Johnson Vision Care, Inc.$579
- Optos, Inc.$352
- Oyster Point Pharma, Inc.$323
- Harrow Eye, LLC$303
- plus $2K from 15 others
What the payments were for
- Travel & lodging$93814%
- Food & beverage$5,37083%
- Entertainment$1612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 42 | $2,319 |
| AbbVie(2 entities) | 14 | $593 |
| Johnson & Johnson Vision Care, Inc. | 8 | $579 |
| Optos, Inc. | 2 | $352 |
| Oyster Point Pharma, Inc. | 9 | $323 |
| Harrow Eye, LLC | 4 | $303 |
| Coopervision Inc. | 5 | $280 |
| Bausch & Lomb Americas Inc. | 4 | $219 |
| Sun Pharmaceutical Industries Inc. | 6 | $210 |
| Novartis | 7 | $198 |
| Dompe US, Inc. | 5 | $160 |
| Biotissue Holdings Inc. | 1 | $151 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $144 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Astellas Pharma Global Development | 1 | $113 |
| Glaukos Corporation | 1 | $110 |
| Tarsus Pharmaceuticals, Inc. | 1 | $75 |
| Genentech USA, Inc. | 1 | $64 |
| Beaver-visitec International, Inc. | 3 | $61 |
| Apellis Pharmaceuticals, Inc. | 1 | $52 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES TOTAL1 Multifocal$1,111
- AIR OPTIX$1,111
- Dailies Aqua Comfort Plus$1,111
- PANORAMIC OPHTHALMOSCOPE$704
- OCT OPHTHALMOSCOPE$513
- Acuvue$505
- NFC-700$352
- Precision 1$260
- Prokera$151
- EYSUVIS$146
- Tecnis IOL$144
- INFUSE$125
- ACTHAR$125
- VEVYE$125
- MyDay Contact Lens$124
- Izervay$113
- CEQUA$110
- iStent inject W$110
- KXL System$110
- Photrexa$110
How this compares
$6,469 in reported general payments places this provider in the 90th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 51 | $73,110 |
| XiidraLifitegrast | 52 | $62,165 |
| Restasis MultidoseCyclosporine | 50 | $45,432 |
| XdemvyLotilaner | 17 | $32,211 |
| EysuvisLoteprednol Etabonate | 32 | $15,419 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,789 |
| TyrvayaVarenicline Tartrate | 13 | $11,167 |
| Latanoprost | 71 | $711 |
| Prednisolone Acetate | 20 | $631 |
| ErythromycinErythromycin Base | 18 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $593 | $118,542101 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $219 | $74,95469 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $75 | $32,21117 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $39 | $15,41932 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $323 | $11,16713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 500 optometrist providers in Louisiana.
Other optometrist in New Orleans
- James LamarNew Orleans$45K
- Breanne McGheeNew Orleans$14K
- Jeanne HermanNew Orleans$7K
- Lynh Chi NguyenNew Orleans$5K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.